Focus on Asthma Care

Back to articles

New first-in-class treatment effective for uncontrolled persistent asthma

KEY POINT

Use of the investigational agent dupilumab, an interleukin-4 and -13 inhibitor, resulted in improved lung function and reduced severe exacerbations in patients with uncontrolled persistent asthma irrespective of baseline eosinophil count, according to results of a study published online in The Lancet.